This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Nov 6;146(19):2280-2281.

doi: 10.1182/blood.2025030748.

Double trouble for a blurry foe: precision strike on BCL11B

Olaf Heidenreich¹

Affiliations

PMID: 41196623
DOI: 10.1182/blood.2025030748

Editorial

Double trouble for a blurry foe: precision strike on BCL11B

Olaf Heidenreich. Blood. 2025.

. 2025 Nov 6;146(19):2280-2281.

doi: 10.1182/blood.2025030748.

Author

Olaf Heidenreich¹

Affiliation

¹ Princess Maxima Center for Pediatric Oncology.

PMID: 41196623
DOI: 10.1182/blood.2025030748

No abstract available

PubMed Disclaimer

Comment on

Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.
Montefiori LE, Iacobucci I, Gao Q, Moore J, Wright WC, Wei H, Baviskar P, Sona S, Jin H, Budhraja A, Lott J, Tatarata QZ, Cheng Z, Khan T, Backhaus Wagner EA, Johnson M, Mehr CM, Freeman B, Janke L, Haferlach T, Geeleher P, Mead PE, Konopleva M, Opferman JT, Mullighan CG. Montefiori LE, et al. Blood. 2025 Nov 6;146(19):2350-2356. doi: 10.1182/blood.2025028985. Blood. 2025. PMID: 40811853 Free PMC article.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems